These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34289341)

  • 1. Development of a novel formulation method to prepare liposomal Epacadostat.
    Tahaghoghi-Hajghorbani S; Khoshkhabar R; Rafiei A; Ajami A; Nikpoor AR; Jaafari MR; Badiee A
    Eur J Pharm Sci; 2021 Oct; 165():105954. PubMed ID: 34289341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression.
    Khoshkhabar R; Yazdani M; Hoda Alavizadeh S; Saberi Z; Arabi L; Reza Jaafari M
    Int Immunopharmacol; 2024 Aug; 137():112437. PubMed ID: 38870880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine.
    Tahaghoghi-Hajghorbani S; Yazdani M; Nikpoor AR; Hatamipour M; Ajami A; Jaafari MR; Badiee A; Rafiei A
    Sci Rep; 2023 Apr; 13(1):5802. PubMed ID: 37037839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
    Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
    J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of doxorubicin and epacadostat via heparin coated pH-sensitive liposomes to suppress the lung metastasis of melanoma.
    Chen Y; Du Q; Zou Y; Guo Q; Huang J; Tao L; Shen X; Peng J
    Int J Pharm; 2020 Jun; 584():119446. PubMed ID: 32439586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
    Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
    Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma.
    Hatamipour M; Jaafari MR; Zangui M; Shakour N; Sahebkar A
    Anticancer Agents Med Chem; 2021; 21(17):2379-2384. PubMed ID: 33596812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
    Panfili E; Mondanelli G; Orabona C; Gargaro M; Volpi C; Belladonna ML; Rossini S; Suvieri C; Pallotta MT
    Front Immunol; 2023; 14():1134551. PubMed ID: 37122718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxgenase: a case of sulfur-substitution affecting distributions in blood cells.
    Wang W; Zhuang X; Sun H; Dong L; Liu Z; Du G; Ye L; Tian J
    Xenobiotica; 2019 Nov; 49(11):1338-1343. PubMed ID: 30507339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
    Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
    Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
    Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
    Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
    Brochez L; Chevolet I; Kruse V
    Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
    Gibney GT; Hamid O; Lutzky J; Olszanski AJ; Mitchell TC; Gajewski TF; Chmielowski B; Hanks BA; Zhao Y; Newton RC; Maleski J; Leopold L; Weber JS
    J Immunother Cancer; 2019 Mar; 7(1):80. PubMed ID: 30894212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
    Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
    Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma.
    Xu G; Wang T; Li Y; Huang Z; Wang X; Zheng J; Yang S; Fan Y; Xiang R
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1089-1094. PubMed ID: 29932010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy.
    Wang Z; Li W; Jiang Y; Tran TB; Cordova LE; Chung J; Kim M; Wondrak G; Erdrich J; Lu J
    Nat Commun; 2023 Nov; 14(1):7235. PubMed ID: 37945606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
    Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
    J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.